NY-ESO-1 TCR-T cell therapy(Anocca AB)

N/A

Report date: 2023/11/08 17:26:14

Base Information

Drug NameNY-ESO-1 TCR-T cell therapy(Anocca AB)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnocca AB
China Registration ClassN/A

Develop Information

Active CompaniesAnocca AB
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A